Find a Physician | How to Contribute | About Us | Clinical Trials
 
Call 312-695-1102 with questions about Clinical Trials
Clinical Trials

Early Phase Clinical Trials (Phase 1 & Phase 2)

A Phase I Study with an Expansion Cohort of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma

The purpose of this study is to test the safety of the combination of multiple drugs: brentuximab vedotin, ipilimumab, and nivolumab, in the treatment of relapsed/refractory Hodgkin lymphoma.

Status: Accepting New Patients
Principal Investigator: Leo Gordon

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin In Stage IIIb/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

The purpose of this study is to assess the safety of nivolumab in combination with Abraxane (nab-paclitaxel) based chemotherapy treatments.

Status: Accepting New Patients
Principal Investigator: Aparna Kalyan

Phase II Study of Pembrolizumab and Capecitabine for Advanced Triple Negative and Hormone-Refractory Breast Cancer

The purpose of this study is to see whether a combination of two different drugs – pembrolizumab and capecitabine – is safe, and if it might be effective in treating metastatic breast cancer.

Status: Accepting New Patients
Principal Investigator: Sarika Jain

A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies

The purpose of this research is to evaluate the safety and tolerability of the investigational drug, INCB053914, and to select the doses that will be studied further in people with advanced cancers or diseases where cells grow too much.

Status: Accepting New Patients
Principal Investigator: Jason Kaplan

A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-negative B lineage Acute Lymphoblastic Leukemia in Adults

This study in being done to determine what affects (good and bad) the therapy blinatumomab has on acute lymphoblastic leukemia (ALL).

Status: Accepting New Patients
Principal Investigator: Shira Dinner

A Phase I-II Trial of DA-EPOCH-R Plus Ixazomib as Frontline Therapy for Patients with MYC-aberrant Lymphoid Malignancies: The DACIPHOR Regimen

The purpose of this study is to evaluate the effects, good and bad of a new drug called ixazomib (also called MLN9708), when it is given along with a common treatment combination, called Dose-Adjusted EPOCH-R (DA-EPOCH-R, for short).

Status: Accepting New Patients
Principal Investigator: Barbara Pro

A Phase 1 Dose-Escalation Study of Intravesical Pembrolizumab and Bacillus Calmette-Guerin (BCG) in Subjects with High Risk and BCG-Refractory Non-Muscle-Invasive Bladder Cancer

The purpose of this study is to evaluate the efficacy (the effect of drug on tumor) and the tolerability (the effect of drug on the body) of Pembrolizumab, when given as a single agent in patients with bladder tumors. Another purpose of the study is to see what tumor characteristics are associated with increased efficacy of the Pembrolizumab.

Status: Accepting New Patients
Principal Investigator: Josh Meeks

A Phase 1 Dose Escalation and Phase 2 Randomized Double-Blind Study of Veliparib in Combination with Carboplatin and Etoposide as a Therapy of Treatment-Naïve Extensive Stage Disease Small Cell Lung Cancer

The main goals of the research study are to determine the highest safe dose of veliparib in combination (given together) with carboplatin and etoposide, to understand how the body absorbs and handles veliparib when given together with carboplatin and etoposide, and to evaluate the safety and tolerability of veliparib when taken without the chemotherapy combination.

Status: Accepting New Patients
Principal Investigator: Young Chae

A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

The purpose of this research study is to compare the good and bad effects of the sequence of immunotherapy (combination of ipilimumab and nivolumab) followed by BRAF inhibitor therapy (combination of dabrafenib and trametinib) if and when the disease becomes resistant, to the sequence of BRAF inhibitor therapy (combination of dabrafenib and trametinib) followed by immunotherapy (combination of ipilimumab and nivolumab) if and when the disease becomes resistant.

Status: Accepting New Patients
Principal Investigator: Sunandana Chandra

A Phase I-II Trial of Brentuximab Vedotin Plus Rituximab as Frontline Therapy for Patients with Lymphomas Associated with Immunosuppression

The purpose of this study is to evaluate how safe and effective the combination of two different drugs (brentuximab vedotin and rituximab) is in patients with certain types of lymphoma.

Status: Accepting New Patients
Principal Investigator: Jason Kaplan

A Phase 3, Randomized, Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy

The purpose of this study is to measure how well and how safe eflornithine is in combination with lomustine, compared to lomustine taken alone, in treating patients whose anaplastic astrocytoma has come back after radiation and chemotherapy.

Status: Accepting New Patients
Principal Investigator: Priya Kumthekar

Phase I/Ib study of nivolumab in combination with Therasphere (yttrium-90) in patients with advanced hepatocellular carcinoma.

The purpose of this study is to identify maximum tolerated dose (MTD), that is, the highest dose of the study drug nivolumab that does not cause unacceptable side effects, for combination treatment of nivolumab and Y-90. Also, to evaluate the efficacy (the effect of drug on your tumor) and the tolerability (the effect of the drug on your body) of nivolumab, when given with standard of care Y-90 (Therasphere).

Status: Accepting New Patients
Principal Investigator: Aparna Kalyan

An International Multicentre Open Label Randomised Phase II Advanced Anal Cancer Trial Comparing Cisplatin plus 5-fluorouracil versus Carboplatin plus Weekly Paclitaxel in Patients with Inoperable Locally Recurrent or Metastatic Disease

The purpose of this study is to establish the standard of care for advanced or metastatic anal cancer. Due to the fact that anal cancer is a relatively rare disease, there is currently no nationally and internationally agreed standard chemotherapy treatment. At present, the most frequently prescribed chemotherapy is a combination of two drugs called cisplatin and 5-fluorouracil. However, a formal comparison of this combination with other chemotherapies (potentially more effective, or equally effective but potentially less toxic) has never been performed.

Status: Accepting New Patients
Principal Investigator: Al Benson III

An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of TAK-659 in Adult Patients with Advanced Solid Tumor and Lymphoma Malignancies

Two of the main purposes of this study are to determine the side effects and risks of TAK-659 and the highest dose of TAK-659 that can be given to patients daily without causing side effects and risks that are too severe.

Status: Accepting New Patients
Principal Investigator: Jason Kaplan

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

To compare overall survival of patients with resected Stage III and IV melanoma treated with high dose interferon alfa-2b versus MK-3475.

Status: Accepting New Patients
Principal Investigator: Sunandana Chandra

A Phase II, open label, clinical trial of pre-surgical and adjuvant treatment of recurrent malignant glioma with Tremelimumab and Durvalumab (MEDI4736) alone and in combination to determine immunologic changes from treatment.

The main purpose of this trial is to investigate the effects of a new class of drugs that help the patient’s immune system attack their tumor (Glioblastoma Multiforme – GBM). These drugs have already shown benefit in some other cancer types and are now being explored in GBM.

Status: Accepting New Patients
Principal Investigator: Jeffrey Raizer

Phase Ib Study of Nivolumab and Dasatinib in Patients with Relapsed/Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

The purpose of this research study is to determine the MTD of nivolumab when given in combination with dasatinib in patients with relapsed/refractory Ph+ ALL.

Status: Accepting New Patients
Principal Investigator: Shira Dinner

A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer

The purpose of this study is to find out what effects (good and/or bad) there are to adding the new investigational drug TAK-700 (also called orteronel) to standard hormone therapy which is used to treat prostate cancer, as compared to the standard of hormone therapy alone. The combination of TAK-700 and standard hormone therapy is considered experimental.

Status: Accepting New Patients
Principal Investigator: Benedito Carneiro

Randomized Phase II Study of Sorafenib with or without Everolimus In Patients with Radioactive Iodine Refractory Hürthle Cell Thyroid Cancer

The purpose of this study is to assess additional benefit of treating your cancer with the addition of Everolimus to Sorafenib and whether these two drugs together do not give serious and intolerable side effects. The addition of everolimus to the usual sorafenib might cause more shrinkage of your cancer and might prevent it from growing but it could also cause more side effects than sorafenib alone. This study will allow the researchers to know whether this treatment with 2 drugs is better, the same, or worse than the usual approach (which is sorafenib alone). To be better, the study drugs should increase the time it takes your cancer to progress by four and a half months or more compared to the usual approach. There will be about 56 people taking part in this study.

Status: Accepting New Patients
Principal Investigator: Maria Matsangou

A Phase II Single Arm Study of Palbociclib in Patients with Metastatic HER2-positive Breast Cancer with Brain Metastasis

The purpose of this study is to evaluate if the study drug palbociclib has anti-tumor activity against the breast cancer that has spread to the brain. And to determine the overall radiographic response rate in the CNS.

Status: Accepting New Patients
Principal Investigator: Cesar Santa-Maria

A Phase 1 Study Of COTI-2 For The Treatment Of Advanced Or Recurrent Gynecologic Malignancies

The main purpose of this study is to learn about and compare the highest tolerable doses of the drug COTI-2 that can be given to patients with advanced or recurrent endometrial, ovarian, primary peritoneal, or fallopian tube cancer.

Status: Accepting New Patients
Principal Investigator: Wilberto Nieves-Neira

A Phase 3, MultiCenter, Open-label, Randomized Study Comparing the Efficacy and Safety of AG-221 versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation

To determine if an investigational agent known as AG-221 is safe and effective in treating Late Stage Acute Myeloid Leukemia, compared with those commonly used treatment options (also called conventional care regimens).

Status: Accepting New Patients
Principal Investigator: Olga Frankfurt

A Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL)

The overall purpose of this study is to determine if JCAR017 is safe and effective as a treatment for adults with B-cell Non-Hodgkin Lymphomas that include Diffuse Large B-cell Lymphoma (Transformed DLBCL from indolent histology and Follicular Lymphoma Grade 3B) and Mantle Cell Lymphoma.

Status: Accepting New Patients
Principal Investigator: Leo Gordon

A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects with INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma

This purpose of this study is to determine the safety and effectiveness of a drug called tazemetostat to treat cancer

Status: Accepting New Patients
Principal Investigator: Mark Agulnik

A Phase II Study of Pazopanib with Oral Topotecan in Patients with Metastatic and Non-resectable Soft Tissue and Bone Sarcomas

The purpose of this clinical research study is to learn if pazopanib when given in combination with topotecan can help to control sarcomas. The safety of this drug combination will also be studied.

Status: Accepting New Patients
Principal Investigator: Mark Agulnik

A Multicenter, Open-Label, Pilot Study of Alisertib (MLN8237), A Novel Inhibitor of Aurora Kinase A, in Adult Patients with Relapsed/Refractory Acute Megakaryoblastic Leukemia or Myelofibrosis (Including Primary and Post-Essential/Post-Polycythemic Myelofibrosis)

The main purpose of the study is to determine how safe and tolerable the study drug, Alisertib, is in patients with AMKL and in patients with MF.

Status: Accepting New Patients
Principal Investigator: Brady Stein

SHERLOC: A Phase 2 Study of MM-121 in Combination with Docetaxel versus Docetaxel Alone in Patients with Heregulin Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer

The main purpose of this study is to find out more about the side effects of MM-121 when combined with docetaxel or pemetrexed, and to learn if cancer cell growth (disease progression) is delayed in people taking MM-121 with docetaxel or pemetrexed.

Status: Accepting New Patients
Principal Investigator: Young Chae

A Prospective, Randomized, Blinded, Placebocontrolled, Phase IIb Trial of an Autologous Tumor Lysate (Tl) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine vs Unloaded YCWP + DC In Stage III and Stage IV (Resected) Melanoma to Prevent Recurrence

The purpose of this study is to (1) produce and test a vaccine that is made from your tumor cells and white blood cells to determine if it can prevent melanoma recurrence; (2) to look at the safety of the vaccine (what side effects it has); and (3) to look at the immune system’s response to this vaccine.

Status: Accepting New Patients
Principal Investigator: Sunandana Chandra

An Open-Label, Phase 1b/2 Study Investigating Recommended Phase 2 Dose, Safety, Tolerability, and Preliminary Efficacy of TAK-659 in Adult Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)

This study is divided into 2 parts. The main purpose of the first part of this study (phase 1b) is to evaluate the side effects and risks of an investigational drug, TAK-659, to identify the highest dose that can be tolerated safely, and to decide upon the recommended dose for the second part of the study. The second part of this study (phase 2) will evaluate how well AML responds to the investigational drug.

Status: Accepting New Patients
Principal Investigator: Olga Frankfurt

last updated: Sat - June 24, 2017 - 03:50 PM

Fetching Clinical Trial!

 

Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.